Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 6/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | BRD3 | Q15059 | 9/20 | 0.41 |
| ▸ | JAK2 | O60674 | 2/20 | 0.35 |
| ▸ | PGR | P06401 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29301626 | 1.00 | PARP1 (0.45) | PARP1CYP2D6BRD3JAK2PGR | |
| SCHEMBL29824463 | 0.86 | CYP2D6 (0.48) | PARP1CYP2D6BRD3 | |
| SCHEMBL29301553 | 0.86 | CYP2D6 (0.48) | PARP1CYP2D6BRD3 | |
| SCHEMBL23537497 | 0.86 | CYP2D6 (0.48) | PARP1CYP2D6BRD3 | |
| SCHEMBL29824412 | 0.85 | PARP1 (0.41) | PARP1CYP2D6BRD3 | |
| SCHEMBL23537417 | 0.85 | PARP1 (0.41) | PARP1CYP2D6BRD3 | |
| SCHEMBL23537222 | 0.83 | PARP1 (0.49) | PARP1CYP2D6 | |
| SCHEMBL29824229 | 0.83 | PARP1 (0.49) | PARP1CYP2D6 | |
| SCHEMBL23537297 | 0.82 | PARP1 (0.40) | PARP1CYP2D6BRD3 | |
| SCHEMBL29824603 | 0.82 | PARP1 (0.40) | PARP1CYP2D6BRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228504-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-11 | — | — | US | disclosed |
| US-20240228504-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-11 | — | — | US | disclosed |
| US-20230108906-A1 | SUBSTITUTED BICYCLIC AND TRICYCLIC UREAS AND AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2023-04-06 | — | — | US | disclosed |
| EP-4149945-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | Arbutus Biopharma Corporation (CA) | 2023-03-22 | — | — | EP | disclosed |
| CN-115551864-A | Substituted tricyclic amides, analogs thereof, and methods of using the same | 爱彼特生物制药公司 | 2022-12-30 | — | — | CN | disclosed |
| EP-4076648-A1 | SUBSTITUTED BICYCLIC AND TRICYCLIC UREAS AND AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | Arbutus Biopharma Corporation (CA) | 2022-10-26 | — | — | EP | disclosed |
| CN-115087486-A | Substituted bicyclic and tricyclic ureas and amides, analogs thereof, and methods of use thereof | 爱彼特生物制药公司 | 2022-09-20 | — | — | CN | disclosed |
| WO-2021229302-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2021-11-18 | — | — | WO | disclosed |
| WO-2021127356-A1 | Substituted Bicyclic and Tricyclic Ureas and Amides, Analogues Thereof, and Methods Using Same | ARBUTUS BIOPHARMA, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228504-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | SLC10A1, NR1H4, SLC10A2 | PARP1 3384/4885CYP2D6 55/4885BRD3 527/4885 |
| US-20230108906-A1 | SUBSTITUTED BICYCLIC AND TRICYCLIC UREAS AND AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | DDC, CDA, HMBS | PARP1 2241/4885CYP2D6 489/4885BRD3 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.